Khazanah Nasional Ventures

Khazanah Nasional is the sovereign wealth fund of Malaysia, with a venture-and-growth investing program that includes high-value strategic healthcare technology investments. Stage focus is Series C, Series D, and growth with checks of $25M+, and AI is a stated focus. Healthcare exposure spans pharma and therapeutics through the IHH Healthcare investment, life sciences tools, and selected late-stage strategic positions. This is institutional sovereign capital, not venture in the typical sense, and the decision-making process reflects that. The right founder for Khazanah is the CEO of a globally significant healthcare or life sciences business at late growth, pre-IPO, or PIPE scale, often with Malaysian or ASEAN strategic relevance and the governance maturity to absorb sovereign capital with the associated reporting and stakeholder dynamics. The wrong founder is anyone earlier than late growth; Khazanah does not do venture-stage commitments in the typical sense, and the firm’s process expects mature financials and global-grade governance. Intro paths run through KL and Singapore institutional capital networks, investment banks operating in regional healthcare M&A including Maybank Investment Bank, CIMB, JPMorgan, and Morgan Stanley, and through co-investing sovereign and PE peers including Temasek, GIC, and major global PE firms active in Asian healthcare. The IHH Healthcare network is also a natural connector for healthcare-specific deal flow. In the pitch, lead with audited financials, governance maturity, and the strategic relevance to Malaysia’s broader healthcare or life sciences ambitions, since Khazanah’s mandate is partly developmental and Malaysian impact factors meaningfully into investment committee. Show clear exit logic, typically IPO on a major exchange or strategic acquisition by global pharma or healthcare players. Be specific about MDA, BPFK, and ASEAN regulatory posture, and about any IHH Healthcare or other Khazanah portfolio synergies. Caveats include the long diligence cycles typical of sovereign wealth, the political-economy considerations that occasionally shape Khazanah’s investment decisions, and the reality that the fund’s healthcare deal cadence is uneven and concentrated in a small number of large positions per year. For mature healthcare businesses with Malaysian or ASEAN strategic relevance, Khazanah is a credible sovereign partner with global scale; for everyone else, the door is closed by stage alone.